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Nutrient deprivation has been shown to cause cancer cell death. To exploit nutrient deprivation as anti-cancer therapy, we
investigated the effects of the anti-metabolite 2-deoxy-D-glucose on breast cancer cells in vitro. This compound has been
shown to inhibit glucose metabolism. Treatment of human breast cancer cell lines with 2-deoxy-D-glucose results in cessation
of cell growth in a dose dependent manner. Cell viability as measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide conversion assay and clonogenic survival are decreased with 2-deoxy-D-glucose treatment indicating that
2-deoxy-D-glucose causes breast cancer cell death. The cell death induced by 2-deoxy-D-glucose was found to be due to
apoptosis as demonstrated by induction of caspase 3 activity and cleavage of poly (ADP-ribose) polymerase. Breast cancer
cells treated with 2-deoxy-D-glucose express higher levels of Glut1 transporter protein as measured by Western blot analysis
and have increased glucose uptake compared to non-treated breast cancer cells. From these results we conclude that 2-
deoxy-D-glucose treatment causes death in human breast cancer cell lines by the activation of the apoptotic pathway. Our
data suggest that breast cancer cells treated with 2-deoxy-D-glucose accelerate their own demise by initially expressing high
levels of glucose transporter protein, which allows increased uptake of 2-deoxy-D-glucose, and subsequent induction of cell
death. These data support the targeting of glucose metabolism as a site for chemotherapeutic intervention by agents such as
2-deoxy-D-glucose.
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Tumour cells are dependent on glycolysis to support their meta-
bolic requirements. Even under aerobic conditions, tumour cells
continue to rely on glycolysis rather than oxidative phosphoryla-
tion (Warburg effect) resulting in high glucose requirements to
generate energy and support metabolic function (Warburg, 1956;
Weber, 1977). Malignant transformation of cultured cells with
oncogenes or onco-viruses results in an absolute increase in the
amount of glucose transported into the cell. This is mediated by
transcriptional activation of the Glut1 glucose transporter gene
resulting in increased levels of glucose transporter mRNA and
protein (Birnbaum et al, 1987; Flier et al, 1987). Many human
cancers have been found to express elevated levels of the Glut1
glucose transporter compared to normal tissues (Yamamoto et al,
1990; Younes et al, 1996). In human breast cancers, high Glut1
expression tends to correlate with tumours having high prolifera-
tive activity and histological score (Brown and Wahl, 1993;
Younes et al, 1995). These ﬁndings have led to the hypothesis that
increased glucose uptake may represent an important regulatory
point in the maintenance of growth and synthetic activity of malig-
nant cells and suppression of apoptosis (Greiner et al, 1994; Kan et
al, 1994; Bentley et al, 2001; Vander Heiden et al, 2001).
Experimental conditions of glucose-deprivation have been
demonstrated to cause apoptosis in many transformed cell lines
(Shim et al, 1998). For example, glucose-deprivation in an interleu-
kin 3 dependent lymphoma cell line and the MCF7/ADR breast
cancer cell line have been found to cause apoptosis (Kan et al,
1994; Lee et al, 1997). Multiple related mechanisms may be
involved in glucose-deprivation induced signalling including the
activation of kinases (mitogen activation protein kinase, c-Jun N-
terminal kinase, Lyn kinase) (Galoforo et al, 1996; Gupta et al,
1997; Liu et al, 1997; Lee et al, 1998), change in the redox state
of the cell (Blackburn et al, 1999; Spitz et al, 2000), or generation
of free radicals (Nomura et al, 1999).
Glucose-deprivation can be mimicked with glucose antagonists.
Glucose analogues have been found to profoundly inhibit glucose
metabolism in cancer cells in vitro and in vivo (Ball et al, 1957;
Laszlo et al, 1958; Kaplan et al, 1990a). Of the many glucose
analogues which have been investigated, 2-deoxy-D-glucose
(2DG) has proved very effective in the inhibition of glucose meta-
bolism and ATP production (Laszlo et al, 1960; Jain et al, 1985;
Kaplan et al, 1990a). 2DG is a structural analogue of glucose
differing at the second carbon atom by the substitution of hydro-
gen for a hydroxyl group (Figure 1A) and appears to selectively
accumulate in cancer cells by metabolic trapping (Gallagher et
al, 1978) due to increased uptake (Waki et al, 1998; Rivenzon-
Segal et al, 2000), high intracellular levels of hexokinase or phos-
phorylating activity (Kaplan et al, 1990a; Arora et al, 1992; Waki
et al, 1997; Aloj et al, 1999), and low intracellular levels of phos-
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Cell killing caused by 2DG has been described in several cell lines
(Jain et al, 1985; Kaplan et al, 1990b; Nomura et al, 1999; Ko et
al, 2001).
To exploit glucose metabolism of cancer cells as a therapeutic
target, we have investigated the effects of 2DG in human breast
cancer cells. In the described series of experiments, we demon-
strate that 2DG inhibits breast cancer cell growth,
clonogenicity, and causes cell death through apoptosis. Breast
cancer cells treated with 2DG express higher levels of the Glut1
transporter protein and exhibit increased uptake of glucose, indi-
cating that cells might enhance their death in response to 2DG
treatment. These results support targeting glucose metabolism
as a target site for chemotherapeutic intervention using
compounds such as 2DG since the initial response of increased
transporter expression and glucose uptake results in accelerated
cellular demise.
MATERIALS AND METHODS
Cell culture
Cell lines SkBr3, MCF-7, BT474, and MDA/MB468, all obtained
from ATCC, were grown in RPMI-1640 media supplemented with
10% heat inactivated fetal calf serum, penicillin (100 units ml
71)
streptomycin (100 mgm l
71), and amphotericin B (0.25 mgm l
71)
in a humidiﬁed atmosphere of 5% CO2 and 95% air at 378C.
For most experiments, cells were seeded at 2.5610
6 cells per 10-
cm diameter tissue culture plate 2 days prior to use.
Clonogenic survival assay
Cells were plated at 4000 cells well
71 in a 96-well plate, allowed
24 h to attach and subsequently exposed for 4 h to 2DG. Cells were
trypsinised, counted, and replated at 400 cells per 60 mm-diameter
culture dish and incubated undisturbed for 14 days at 378Ci na
humidiﬁed incubator. Colonies were counted after ﬁxing with
methanol: acetic acid (3:1) and staining with 0.25% crystal violet.
Colonies containing more than 25 cells were scored as positive.
Each data point was performed in triplicate. Data were normalised
to sham treated control cell plating efﬁciencies. Plating efﬁciency of
sham treated cells was 38–50%, calculated as the number of colo-
nies observed divided by the number of trypsinised cells plated.
Error bars represent the range of values. Each data point represents
the average of three samples.
Measurement of [
14C]3-O-methyl-glucose (3-O-MG)
uptake
One to two days prior to the experiment, cells were plated in tripli-
cate at 10
4 cells cm
72 in 6-well plates (35 mm diameter wells).
Cells were incubated with 8 mM 2DG for 4 h, rinsed with warm
PBS, and 950 ml of warm uptake media (128 mM NaCl, 4.7 mM
KCl, 1.25 mM MgSO4,1 0 m M NaH2PO4, 1.25 mM CaCl2,
pH 7.4) was added to each well. Where indicated, 50 mM of cyto-
chalasin B was added in the warm uptake media (Hamrahian et al,
1999). Plates were incubated at 378C for 6 min and subsequently
50 mlo f[
3H]3-O-methyl-glucose was added (1 mM 3-O-methyl-
glucose, 20 mCi ml
71 of [
14C]3-O-methyl-glucose). Incubation
was continued for the indicated times. The reactions were stopped
by the addition of cold PBS. The cells were washed ﬁve times with
cold PBS and lysed with 1 mM NaOH. Ten microlitres from each
sample was used for protein concentration analysis (Bio-Rad DC
Protein Assay). Scintillation ﬂuid was added to the remainder of
the sample for scintillation counting. Glucose uptake was calculated
as mmoles uptake per mg protein. 3-O-methyl-D-[
14C]glucose
(56 mCi mmol
71) was purchased from Amersham Corp.
MTT assay
Cells (2500 per well) were plated in quadruplicate in 96-well
culture plates. Following cell adherence (24–48 h), experimental
media containing 2DG or control media was added and incubation
continued for the indicated times at 378C. MTT (0.5 mg ml
71 in
PBS) was added to each well and incubation continued at 378C
for an additional 4 h. The media was then discarded and 200 ml
of DMSO was added to each well to solubilise the coloured forma-
zan product. Absorbance was read at 550 nm on a scanning
microtiter spectrophotometer plate reader (Bio-Rad) after agitating
the plated for 5 min on a shaker. All data is expressed relative to
untreated cells in the same experiment which are standardised to
100% (Carmichael et al, 1987).
Glut1 protein Western blot analysis
Cells were plated at 10
4 cells cm
72 and grown in the presence of
2DG for the times indicated in the ﬁgures. At each time point, cells
were collected, and lysed by the addition of HER buffer (250 mM
sucrose, 10 mM HEPES, 1 mM EDTA (pH 8.0)). DNA was frag-
mented by passing the solution through a 21g needle 3–4 times.
Protein concentration was determined using the Bio-Rad DC
Protein Assay. Samples were mixed with 26Laemmli lysis buffer
(16=2.4 M glycerol, 0.14 M Tris, pH 6.8, 0.21 M sodium dodecyl-
sulphate, 1.28 M mercaptoethanol, 0.3 mM bromophenol blue).
Protein (50 mg) was added per lane on a 10% separation SDS-poly-
acrylamide gel (acrylamide:bis-acrylamide 20:1). Gels were run at
200 V in 25 mM Tris, 192 mM Glycine, 0.1% SDS and resolved
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Figure 1 (A) Structural comparison of glucose and 2-deoxy-D-glucose.
2DG and glucose differ at the second carbon. (B) Schematic diagram of 2-
DG action. 2DG enters the cell through the glucose transporter and is
phosphorylated by hexokinase. Due to low levels of intracellular phospha-
tase, 2-DG-PO4 is trapped in the cell. 2-DG-PO4 is unable to undergo
further metabolism. High intracellular levels of 2-DG-6-PO4 cause allosteric
and competitive inhibition of hexokinase. This results in inhibition of glu-
cose metabolism.
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25 mM Tris, 192 mM Glycine, 20% v v
71 methanol buffer. To
block non-speciﬁc sites, ﬁlters were incubated with Blotto (5%
nonfat dry milk, 0.02% sodium azide, 0.01% Antifoam A in
PBS) for 1 h at room temperature. Blots were probed with anti-
Glut1 polyclonal antibody by incubation at room temperature for
1 h. This antibody was generated against the C-terminal 13 amino
acids (gift from Dr. Mike Meckler) diluted 1:1000, or purchased
from DAKO (Marshall et al, 1993). The membrane was washed
with PBS and subsequently incubated with the secondary antibody
horseradish peroxidase conjugated donkey anti-rabbit IgG (diluted
1:500) for 1–2 h. The membrane was rinsed in Blotto, and the
amount of binding visualised by using enhanced chemilumines-
cence method (ECL, Amersham Pharmacia Biotech). Film
exposure ranged from 10 s to 1 min. The blots were stained with
0.5% Ponceau in 5% TCA to conﬁrm uniform protein transfer
prior to antibody reactions. Where indicated the membranes were
stripped in 100 mM b-mercaptoethanol, 2% SDS, 62.5 mM Tris-
HCl pH 6.8 at 558C for 30 min and re-probed with anti-actin anti-
body (diluted 1:40 obtained from Calbiochem) for 1 h at room
temperature. Secondary antibody incubation and development
were performed as described.
PARP Western blot analysis
Cells were grown as above and lysed with buffer containing
62.5 mM Tris pH 6.8, 8 M deionised urea, 10% glycerol, 2% SDS
and protease inhibitor stock solutions (ﬁnal concentration:
1 mgm l
71 Leupeptin, 1 mgm l
71 antipain, 1 mgm l
71 benzami-
dine, trypsin inhibitor 5 mgm l
71,1 mgm l
71 chymostatin,
1 mgm l
71 pepstatin A, 87 mgm l
71 PMSF). Samples were soni-
cated for 20 s to fragment the DNA. Samples containing 50 mg
of protein were heated to 658C and size-separated protein on
7.5% gel. Protein was transferred to nitrocellulose as described
above. After blocking non-speciﬁc binding sites with Blotto, ﬁlters
were probed with anti-PARP antibody diluted 1:5000 (Biomol) for
2.5 h at room temperature. Filters were washed with PBS and
subsequently incubated with the secondary antibody anti-mouse
Ig conjugated to horseradish peroxidase diluted 1:2000 for 1 h
at room temperature. Antibody binding was determined using
ECL as described above. Positive controls were SkBr3 cells treated
with 2 mM staurosporine for 6 h.
Caspase-3 assay
Caspase 3 activity was determined using ApoAlert Caspase-3 Assay
Kit (Clontech). 2610
6 cells were used for each time point. After
the indicated treatments, cells were lysed by the addition of 50 ml
of the provided lysis buffer and incubation on ice for 10 min.
The non-soluble debris was removed by centrifugation at
14000 r.p.m. for 3 min. Fifty microlitres of the supernatant was
mixed with 50 ml of the provided reaction buffer. Where indicated,
0.5–1 mlo f1m M DEVD-Fmk inhibitor was preincubated with the
indicated specimens at 378C for 30 min. Five microlitres of
substrate 1 mM DEVD-pNA was added to each sample and the
reaction allowed to run at 378C for 1 h. Samples incubated without
substrate served as the negative control. Absorbance was measured
at 405 nm and using 655 nm as an internal reference.
RESULTS
Effect of 2DG on cell growth, clonogenic survival, and
viability
Glucose-deprivation has been shown to cause apoptosis in breast
cancer cell lines (Lee et al, 1997). To determine whether a similar
result could be achieved using the non-metabolisable glucose
analogue 2DG, which is known to inhibit glucose metabolism
(Wick et al, 1957), four human breast cancer cell lines MCF-7,
SkBr3, BT549, and MDA/MB468 were grown in the presence of
varying concentrations of 2DG. Representative growth curves from
two of these cell lines are shown in Figure 2. 2DG was added to
cells on day zero at concentrations ranging from 4–12 mM.A s
seen in Figure 2A, growth of MDA/MB468 cells was completely
inhibited by treatment with 8 mM 2DG. Treatment with 4 mM
2DG resulted in approximately 30% inhibition of cell growth. Of
the breast cancer cell lines tested, SkBr3 was the most sensitive
to the growth inhibitory effects of 2DG. Cell growth was comple-
tely inhibited at 4 mM 2DG (Figure 2B). This represents a ratio of
2DG to glucose in the culture media of 1:4.25. This is consistent
with previous cell culture studies in which a ratio of 1 part 2DG to
3 parts glucose inhibited glycolysis approximately 50% (Laszlo et
al, 1960). These experiments indicate that 2DG inhibits breast
cancer cell growth which may be due to either growth arrest or cell
death and that competition for essential sites of inhibition is in
favour of 2DG.
It has previously been reported that normal cells undergo with-
drawal from the cell cycle during nutrient or glucose deprivation
rather than undergo cell death (Shim et al, 1998). To determine
whether treatment with 2DG resulted in cell death or withdrawal
from the cell cycle, clonogenic survival and MTT assays were
performed. For the clonogenic survival experiments, SkBr3 cells
were treated with 2DG for 4 h, re-cultured at low density in
normal media, and colony formation determined at 14 days. As
seen in Figure 3, there is a dose dependent decrease in clonogenic
survival with 2DG treatment. Treatment with 4 mM 2DG for 4 h
results in 50% decrease in cell survival at 14 days compared to
non-treated control cells. These results indicate that 2DG treatment
causes cell death as reﬂected by decreased clonogenicity rather than
withdrawal from the cell cycle.
MTT is reduced by viable cells to a coloured formazan product
and has been previously found to correlate with clonogenic survival
and has been used for chemosensitivity testing (Carmichael et al,
1987). To determine whether reduction of MTT paralleled clono-
genic survival, breast cancer cell lines were treated with varying
concentrations of 2DG and spectrophotometric conversion of
MTT measured. As seen in Figure 4, 2DG treatment of three breast
cancer cell lines for 4 h resulted in a dose dependent decrease in
absorption at 550 nm indicting decreased reduction of MTT to
its formazan product. Treatment with 1 mM 2DG resulted in an
approximately 40% decrease in the reduction of MTT by SkBr3
cells, approximately 25% decrease by MCF7 cells, and no change
by the MDA/MB468 cell line. When SkBr3 cells treated with
3m M 2DG for 24 h and allowed to recover for 6 h a slight increase
in MTT reduction is observed (50% vs 61%, data not shown). As
observed in the cell growth experiments, the SkBr3 cell line
appeared to be more sensitive to the effects of 2DG than MCF-7
and MBA/MB468 breast cancer cell lines in this assay. In addition,
these results parallel the results of the clonogenic survival assay and
indicate that the MTT conversion correlates with cell survival with
2DG treated cells.
Caspase 3 activity and PARP cleavage with 2DG treatment
Clonogenic survival and MTT assays encompass all types of cell
death including necrosis and apoptosis. Apoptotic cell death is
an active death process and can be inferred by measuring the acti-
vation of caspases and the cleavage of key enzymes. To determine
whether the cell death caused by 2DG involves apoptosis, cells were
examined for caspase 3 activity and PARP cleavage. Caspase 3 is an
essential protease activated during apoptotic cascade (Gross et al,
1999). Caspase 3 activity was measured in SkBr3 cells after treat-
ment with 2DG using a spectrophotometric assay based on the
cleavage of DEVD-pNA, a substrate for caspase 3. As seen in Figure
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increase of caspase 3 activity. Caspase 3 activity increased by
three-fold over control cells after treatment with 16 mM 2DG for
6 h. This activity was inhibited by pre-incubation with the caspase
3 inhibitor DEVD-FMK.
Poly (ADP-ribose) polymerase (PARP) is involved in DNA clea-
vage during apoptosis. During apoptosis the 116 kDa PARP
enzyme is cleaved by caspases to an 89 kDa form which is no long-
er stimulated by nicked DNA (Shah et al, 1995). PARP cleavage
was determined after treatment of SkBr3 cells with 2DG. In this
experiment, SkBr3 cells were treated with either 12 mM 2DG for
6 h or 2 mM staurosporine. Staurosporine has previously been
shown to be a potent inducer of apoptosis and was used as a posi-
tive control (Tafani et al, 2001). Cleavage of PARP was determined
by Western blot analysis using a monoclonal antibody to PARP. As
seen in Figure 6, control cells had undetectable amounts of the
PARP cleavage product (lane 1). In contrast, SkBr3 cells with
2DG or staurosporine resulted in the appearance of the 89kDa
PARP cleavage product. Cells treated with 2DG had approximately
20% cleavage of the protein (lane 3). In addition, 2DG treatment
of SkBr3 cells leads to DNA cleavage (unpublished data). These
results together with the results of the caspase 3 activity experi-
ments indicate that cell death caused by 2DG in SkBr3 cells
occurs in part through apoptosis.
Glut1 transporter expression and glucose uptake with 2DG
treatment
The Glut1 glucose transporter is an integral membrane glycopro-
tein and is responsible for constitutive glucose uptake in breast
cancer cells. Glut1 protein expression is increased in cancer cells
and has been reported to increase during cellular stress and upon
glucose deprivation (Kitzman et al, 1993; Blackburn et al, 1999).
Glut1 contains an N-glycosylation consensus sequence in the ﬁrst
exofacial loop. As a result of heterogeneous glycosylation at this
site, the transporter migrates as a broad band on SDS–PAGE gels
(Marshall et al, 1993). Previous studies have demonstrated that
glucose deprivation alters the glycosylation pattern of Glut1 result-
ing in a lower molecular weight species of the transporter which
migrates as an approximately 37 kDa protein (Kitzman et al,
1993). This transporter species undergoes appropriate trafﬁcking
to the plasma membrane (MacMahon and Frost, 1995; Macmahon
et al, 2000). To determine the effect of 2DG on Glut1 transporter
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Figure 2 Effect of 2-DG on growth of breast cancer cell lines. SkBr3 and
MDA/MB468 breast cancer cell lines were grown in the absence or pre-
sence of various concentrations of 2DG. 2DG was added on day zero
and the media was not changed during the duration of the experiment. Cell
number was determined daily. Each point represents triplicate cultures.
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Figure 3 Clonogenic survival after 2DG treatment. SkBr3 cells were
treated with varying concentrations of 2DG for 4 h and replated at low
density. Colonies were counted 14 days after plating and those containing
25 cells or greater were scored as positive. Each point represents triplicate
cultures.
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Figure 4 MTT conversion after 2DG treatment. SkBr3, MDA/MB468,
and MCF7 cells were incubated with the indicated concentrations of
2DG for 4 h. MTT was added the amount of reduced formazan product
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Figure 5 Caspase 3 activation in SkBr3 cells treated with 2DG. SkBr3
cells were treated with 16 mM 2DG for the 4 or 6 h. Cells were harvested
and caspase 3 activity measured using a spectrophotometric assay accord-
ing to the manufacturer’s instructions. The caspase 3 inhibitor DEVD-FMK
was added 30 min prior to the addition of substrate in cells which had been
incubated with 16 mM 2DG for 6 h. Each point represents the average of
triplicate cultures. Control cells were incubated for 6 h in the presence of
media only.
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treatment with 8 mM 2DG for 48 or 72 h, and Glut1 expression
determined by Western blot analysis using a rabbit polyclonal anti-
body prepared to a 13 amino acid C-terminal fragment of Glut1
(Marshall et al, 1993). Fully glycosylated Glut1 migrates as a broad
band at approximately 47 kDa. This can be seen in Figure 7, lanes
1 and 3. Control lysates demonstrating high Glut1 transporter
expression are protein isolated from human placenta (lane 1)
and plasma membranes isolated from Xenopus oocytes injected
with a human Glut1 expression vector (lane 3) (Carayannopoulos
et al, 2000). Lane 2 represents protein isolated from sham injected
Xenopus oocytes. SkBr3 cells were incubated with either 0 or 8 mM
2DG for 48 or 72 h and protein extracts prepared. As seen in lanes
5 and 7, 2DG treatment results in the appearance of a lower mole-
cular weight glycoform of Glut1 is seen which migrates as a 37-kDa
protein. This is in contrast to protein isolated from cells which
were not incubated with 2DG which had very low levels of Glut
1 protein (Figure 7, lanes 4 and 6). In addition, there is greater
intensity of the bands reﬂecting higher levels of Glut1 protein.
The same blot probed with anti-actin antibody demonstrated simi-
lar amounts of actin in each sample. This experiment indicates that
2DG treatment of SkBr3 cells results in increased amounts of Glut1
protein as well as a lower molecular weight protein which is likely
the result of an altered glycosylation pattern.
To determine whether glucose uptake increased or decreased
with 2DG treatment, glucose uptake was measured in SkBr3 cells
after treatment with 8 mM 2DG for 4 h using the non-metabolisa-
ble glucose analogue 3-O-methyl-glucose (3-O-MG). 3-O-MG is
not appreciably phosphorylated by cells and reaches equilibrium
between extracellular and intracellular spaces. Speciﬁc uptake of
3-O-MG by the Glut1 transporter is inhibited by cytochalasin B
(Hamrahian et al, 1999). As shown in Figure 8, 3-O-MG uptake
is three-fold higher in 2DG treated cells than control cells.
Increased uptake of 3-O-MG observed with 2DG treatment was
inhibited by pretreatment with cytochalasin B. This data indicates
that 2DG treatment of breast cancer cells results in increased
glucose uptake which may be due to higher levels of Glut1 protein.
DISCUSSION
Breast cancers exhibit an increased rate of glucose uptake and
express high levels of glucose transporter protein (Wahl et al,
1991; Brown and Wahl, 1993; Younes et al, 1995). Recently,
glucose-deprivation has been reported to cause apoptosis in breast
cancer cells (Lee et al, 1997). These observations lead us to
hypothesise that interference with glucose metabolism by non-
metabolisable glucose analogues would lead to apoptosis in breast
cancer cells. Previous studies have demonstrated that interference
with glycolysis by the non-metabolisable glucose analogue 2DG
can cause cell killing through interference with glycolysis (Kaplan
et al, 1990a; Nomura et al, 1999; Ko et al, 2001). The experimental
results presented here extend previous observations and conﬁrm
our hypothesis by demonstrating that glucose-deprivation induced
by 2DG leads to cessation of cell growth, decreases clonogenicity,
and causes apoptosis in breast cancer cell lines. Furthermore, breast
cancer cells treated with 2DG express higher levels of Glut1 trans-
porter and demonstrate increased glucose uptake as a result of
oxidative stress. Therefore, 2DG appears to be an effective agent
for causing breast cancer cell death due to the initial response of
accelerated glucose uptake by the stressed cells.
It has been hypothesised that increased glucose uptake may
represent an important regulatory point in maintaining the growth
and synthetic activity of malignant cells and suppression of apop-
tosis (Greiner et al, 1994; Kan et al, 1994). For example, c-Myc
transformed rat ﬁbroblasts up-regulate glucose transport and glyco-
lytic gene expression through trans-activation (Osthus et al, 2000).
These cells will undergo apoptosis upon withdrawal of glucose
(Shim et al, 1998). In normal cells, growth is regulated by external
growth signals and nutrient support (Rathmell et al, 2000; Vander
Heiden et al, 2001). Cancer cells, in contrast, have lost responsive-
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Figure 6 PARP activation by SkBr3 cells treated with 2-DG. Cells were
treated for 6 h with 12 mM 2DG or 2 mM staurosporine (+control). Wes-
tern blot analysis was performed using a monoclonal antibody to PARP.
Normal (uncleaved) and the PARP cleavage product are indicated.
Glut1 —
Actin
P
l
a
c
e
n
t
a
–
C
o
n
t
r
o
l
+
C
o
n
t
r
o
l
M
a
r
k
e
r
0       8 0        8
— 61 KDa
— 49 KDa
1         2        3             4        5       6           7
Figure 7 Glut-1 transporter protein levels in breast cancer cells lines
treated with 2-DG. SkBr3 breast cancer cells were treated with 2DG for
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size separated on a 10% polyacrylamide gel. A Western blot was per-
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weight markers are labelled. The protein blot was reacted with anti-actin
antibody after removal of the Glut1 antibody (lower panel).
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Figure 8 Glucose uptake by SkBr3 cells treated with 2-DG. SkBr3 cells
were treated with 8 mM 2-DG and [
14C]3-O-methyl-glucose uptake mea-
sured. Cytochalasin B (50 mM) was added simultaneously with the radioac-
tive glucose.
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nutrient supply in the form of glucose likely plays a unique role
in maintaining cancer cell viability. Thus, normal and transformed
cells respond to nutrient depletion or glucose-deprivation in
opposing manners. Whereas normal cells compensate by increased
glucose transporter expression or modiﬁcation, transformed cells
are stressed by glucose-deprivation leading to the expression of
an array of stress related genes, which is subsequently followed
by cell death. In many normal cell types, glucose deprivation
results in an increase in the maximum velocity of glucose transport
(Kitzman et al, 1993). This has been attributed to one of several
mechanisms; translocation of transporter from an intracellular
compartment to the plasma membrane (Haspel et al, 1991),
changes in the glycosylation pattern of the Glut1 transporter with
decreased turnover of the protein (Macmahon and Frost, 1995),
or by increased synthesis of m RNA and protein (Reed et al,
1990; von der Crone et al, 2000). For example, pre-adipocyte cell
lines respond to glucose starvation by increasing transporter
expression reﬂected in elevated levels of Glut1 transporter mRNA
and protein (Reed et al, 1990). 3T3 cells respond to glucose-depri-
vation by conversion of the native Glut1 transporter to an
incompletely glycosylated form, while increasing basal transport
4.5-fold (Reed et al, 1990; Macmahon and Frost, 1995). Prolonged
glucose deprivation, in non-transformed cell lines, causes cell-cycle
arrest in G0/G1, which is reversible (Shim et al, 1998). In contrast,
many transformed cell lines respond to glucose deprivation initially
by expression of an array of stress related genes and subsequently
undergoing apoptosis (Lee and Corry, 1998). For example, early
in glucose deprivation, MCF7/Adr cells have increased levels of
Lyn and c-Jun kinases as well as increased expression of bFGF
and c-Myc mRNAs (Galoforo et al, 1996; Gupta et al, 1997; Liu
et al, 1997; Lee et al, 1998). These results support the hypothesis
that cancer cells are uniquely sensitive to glucose-deprivation and
glucose-deprivation results in cellular stress and subsequent cyto-
toxicity.
Glucose-deprivation can be mimicked with glucose antagonists.
Glucose analogues have been found to profoundly inhibit glucose
metabolism in cancer cells in vitro as well as in vivo (Ball et al,
1957; Laszlo et al, 1960). Of the many glucose analogues, which
have been investigated, 2DG appears to be the most effective in
inhibiting glycolysis (Laszlo et al, 1958). 2DG is a structural analo-
gue of glucose differing at the second carbon atom by the
substitution of hydrogen for a hydroxyl group and appears to
selectively accumulate in cancer cells (Figure 1). 2DG undergoes
facilitated diffusion into cells via glucose transporters. Once intra-
cellular, 2DG is phosphorylated by hexokinase to 2-deoxy-D-
glucose-6-phosphate (2-DG-6-P). 2-DG-6-P is not a substrate for
glucose-6-phosphate dehydrogenase or phosphohexoisomerase
(Wick et al, 1957). Therefore, once formed, 2-DG-6-P is not
further metabolised and will accumulate in the cell until de-phos-
phorylated by phosphorylase (Gallagher et al, 1978; Kern and
Norton, 1987; Nelson et al, 1996). In malignant cells, speciﬁc accu-
mulation of 2DG is attributed to several mechanisms; increased
glucose transporter expression resulting in increased uptake (Waki
et al, 1998), increased hexokinase activity or phosphorylating activ-
ity resulting in trapping (Kaplan et al, 1990a; Aloj et al, 1999), and
low phosphorylase activity resulting in accumulation (Kern and
Norton, 1987; Nelson et al, 1996). Inhibition of glycolysis by 2-
DG is thought to occur by inhibition of key glycolytic enzymes
such as phosphohexoisomerase (Horton et al, 1982) as well as
depletion of high energy compounds. 2-DG-6-P may act as a
potent Pi trap resulting in depletion of intracellular stores. Low
Pi rapidly leads to dephosphorylation of ATP with a concomitant
increase in AMP. High AMP and low Pi stimulates AMP deami-
nase, which converts AMP to inosine and leads to a decrease in
the total adenine pool. The low Pi and ATP makes hexokinase
far more susceptible to inhibition by G-6-P which may occur by
feedback inhibition and/or allosteric inhibition (Ardehali et al,
1996, 1999).
Hexokinase may be the key regulator in 2DG-induced apoptosis.
Hexokinase is the ﬁrst enzyme of the glycolytic reaction Gluco-
se+MgATP -4Glucose-6-PO4 + MgADP which commits glucose
to undergo metabolism. The phosphorylation of glucose by hexo-
kinase ensures glucose entry into cells via facilitated diffusion
along a downhill concentration gradient. Four isoenzymes of hexo-
kinase are found in mammalian tissues and are subject to allosteric
inhibition by the product Glucose-6-PO4 (Wilson, 1997). Type II
hexokinase, the isoform over-expressed in transformed cells, has
the highest Km for glucose (Parry and Pedersen, 1983; Rempel et
al, 1996). Markedly elevated levels of hexokinase II have been
described in many malignant cell lines and unlike normal tissue,
50–80% of the enzyme is bound to the mitochondrial fraction,
where it is thought to have preferential access to intramitochond-
rially generated ATP and be more resistant to Glucose-6-PO4
inhibition (Arora and Pedersen, 1988; Arora et al, 1992). In addi-
tion, hexokinase forms one component of the proposed
permeability transition pore, which is involved in mitochondria
depolarisation following apoptotic signals (Gross et al, 1999).
Recently published data supports a role of hexokinase activity in
the prevention of apoptosis mediated by Akt (Gottlob et al,
2001). Thus, it is possible that hexokinase expressed in cancer cells
may be uniquely sensitive to 2DG which may have a direct effect
on the apoptotic signal pathway through its role as a member of
the permeability transition pore complex.
A related mechanism for the triggering of apoptosis by glucose-
deprivation or 2DG may be induction of stress-related signals
caused by an imbalance in the energy state of the cell subsequent
to ATP depletion. One method to avoid apoptosis would be to
maintain a favourable energy balance. Should the latter fall below
a certain crucial point, the pre-existing program for apoptosis
would be executed through the expression of stress related genes
(Kan et al, 1994). Previous studies have shown that 2DG inhibits
the rate of glucose usage and glycolysis cancer cell lines by 15–
40% resulting in reduced ATP levels by nearly 40% tested cell lines
(Kaplan et al, 1991; Dwarkanath et al, 2001). Glucose-deprivation
results in activation of the MAP kinase pathway as a result of
oxidative stress (Lee et al, 1998; Blackburn et al, 1999; Spitz et
al, 2000). This pathway is suppressed by over-expression of Bcl-2
which is reported to suppress apoptogenic activity involving mito-
chondria through an antioxidant pathway (Hockenbery et al, 1993;
Zhong et al, 1993; Lee et al, 1997; Lee and Corry, 1998; Shim et al,
1998). This would support a role for alteration in the energy
balance of the cell in induction of apoptosis with glucose depriva-
tion or 2DG treatment.
In this report we present data demonstrating that 2DG treat-
ment of breast cancer cells leads to cell death which occurs in
part by apoptosis. Four breast cancer cell lines were tested which
demonstrated varying sensitivity to the cytotoxic effect of 2DG.
SkBr3 cells were the most sensitive to the effects of 2DG demon-
strating a 50% decrease in clonogenicity at a concentration of
4m M 2DG. Variability to 2DG induced cytotoxicity has been
previously reported and related to a multi-drug resistant phenotype
(Kaplan et al, 1991). However, variability of 2DG induced cytotoxi-
city may be related to the complexity of uptake and processing or
to the levels of pro-apoptotic or anti-apoptotic proteins (Amund-
son et al, 2000). We have further demonstrated that 2DG causes
cell death rather than withdrawal from the cell cycle using clono-
genic survival. The mechanism of cell death induced by 2DG
appears to be by apoptosis as demonstrated by capase 3 and PARP
activation. Slightly higher concentrations of 2DG were required to
observe a signiﬁcant amount of apoptosis compared with clono-
genic survival in SkBr3 cells. This would be consistent with 2DG
causing cell death by methods other than apoptosis exclusively
such as necrosis (Sperandio et al, 2000; Tannock and Lee, 2001).
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transporter expression (Fisher and Frost, 1996). Under these condi-
tions, an incompletely glycosylated form of Glut1 is synthesised
which migrates as a 37 kDa protein (Reed et al, 1990; Kitzman
et al, 1993; Macmahon et al, 2000). Our experiments demonstrate
a similar response upon treatment of breast cancer cells with 2DG.
2DG treatment of breast cancer cells resulted in an increased
glucose uptake as well as expression of higher levels of Glut1
glucose transporter. A lower molecular weight Glut1 protein was
detected which likely represents an incomplete glycosylated form.
From our results, we hypothesise that breast cancer cells treated
with 2DG accelerate their own demise as a result of increased
glucose transport as an initial response to 2DG.
Two properties of 2-DG, inhibition of glycolysis and preferen-
tial accumulation in cancer cells have formed the basis for further
investigating the mechanism of 2DG for use as an anti-tumour
agent. We speculate that cancer cells initially treated with 2DG
exhibit a stress response due to a depletion of intracellular energy.
The stress response results in increased levels of glucose transpor-
ter expression and increased glucose uptake, which allows more
2DG to enter the cell. As a consequence of high intracellular
concentrations 2DG, hexokinase and hexose phosphate isomerase
are inhibited, energy stores such as ATP are further depleted,
and the cell activates the cell death pathway. Cancer cells are
dependent on glycolysis for energy production and appear to be
uniquely sensitive to glucose-deprivation and the effects of 2DG
(Kaplan et al, 1991). The concentrations of 2DG which we
observe to be cytotoxic to breast cancer cells in vitro are achiev-
able in vivo (Mohanti et al, 1996). In several animal models of
experimental malignancies tumour growth was inhibited with
2DG treatment (Laszlo et al, 1960; Kern and Norton, 1987; Ko
et al, 2001). Clinical experience with 2DG has been favorable
but limited (Landau et al, 1958; Mohanti et al, 1996). We think
interference with glucose metabolism by tumour speciﬁc glucose
analogues such as 2DG may serve as an effective agent or sensi-
tiser to other therapeutic modalities especially in multidrug
resistant cells.
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